Abstract
The evidence available from which to guide therapy for pediatric heart failure is limited. Although there are many reasons for this, the greatest obstacles in developing this evidence base are due to the significant challenges inherent in performing well-designed drug trials in pediatric heart failure. This perspective will define many of these obstacles and will propose potential structures for the development and implementation of drug trials in pediatric heart failure.